NSE ScannerComparison · NSE · data 2026-11-01
Alkem Laboratories Ltd. vs Glenmark Pharmaceuticals Limited
In plain words
Size: Glenmark Pharmaceuticals Limited is about 1.1 times the market value of Alkem Laboratories Ltd..
Valuation (P/E): Glenmark Pharmaceuticals Limited 36.1 vs Alkem Laboratories Ltd. 28.4.
Return on equity: Alkem Laboratories Ltd. 17.8% vs Glenmark Pharmaceuticals Limited 14.1%.
Profit growth over 3 years: Glenmark Pharmaceuticals Limited 66.1% a year vs Alkem Laboratories Ltd. 32.7% a year.
Debt to equity: Alkem Laboratories Ltd. 0.15 vs Glenmark Pharmaceuticals Limited 0.06.
Differences in the numbers, not a recommendation of either stock.
Side by side
| ALKEM | GLENMARK | |
|---|---|---|
| Price | ₹5,113.5 | ₹2,298.7 |
| Market cap | ₹61,277 cr | ₹65,137 cr |
| P/E | 28.4 | 36.1 |
| P/B | — | — |
| ROE | 17.8% | 14.1% |
| ROCE | 17.8% | 29.2% |
| Debt / equity | 0.15 | 0.06 |
| Operating margin | 17.5% | 20.2% |
| Dividend yield | 1.03% | 0.22% |
| Sales growth, 3 years (yearly) | 8.2% | 13.6% |
| Profit growth, 3 years (yearly) | 32.7% | 66.1% |
| 1-year return | -7.7% | 24.1% |
| Revenue, last 12 months | ₹15,081 cr | ₹17,737 cr |
| Net profit, last 12 months | ₹2,158 cr | ₹1,798 cr |
| Latest quarter | Jun 2026 | Jun 2026 |
| Quarter net profit | ₹520 cr | ₹483 cr |
| Quarter profit vs a year earlier | — | +930.3% |
| Promoter holding | 53.04% | 46.65% |
| Health check | Strong (6.8/10) | Strong (8.2/10) |
Common questions
Which has a higher P/E, Alkem Laboratories Ltd. or Glenmark Pharmaceuticals Limited?
Glenmark Pharmaceuticals Limited trades at the higher P/E (36.1 against 28.4). A higher P/E means the market pays more for each rupee of past earnings; on its own it does not say which is better.
Which earns a higher return on equity?
Alkem Laboratories Ltd. (17.8% against 14.1%).
Which carries more debt?
Alkem Laboratories Ltd. has the higher debt-to-equity ratio (0.15 against 0.06).